NCT05874414招募中1 期
Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Genfit20 个研究点 分布在 2 个国家目标入组 98 人开始时间: 2023年8月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 98
- 试验地点
- 20
- 主要终点
- Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b)
研究概览
简要总结
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed intrahepatic CCA with a documented KRAS mutation.
- •Patients greater than or equal to 18 years of age.
- •Patients must have disease progression that is not amenable to potentially curative treatment.
- •Patients must have received one or two lines of chemotherapy.
- •Patients must have at least one measurable disease by RECIST v1.
- •Performance status (ECOG) 0-
- •Adequate organ baseline function defined as follows: absolute neutrophil count ≥1000 cells/μL, platelet count ≥75,000 cells/μL, hemoglobin ≥9 g/dL, aspartate aminotransferase or alanine aminotransferase less than or equal to 3 × upper limit of normal, estimated glomerular filtration rate ≥60 mL/min, corrected QT interval by Fridericia's (QTcF) interval ≤470 msec.
- •Women of childbearing potential must present with a negative serum pregnancy test and agree to use adequate contraception during the study and until 6 months after the end of treatment. Male patients with women partners of childbearing potential must agree with the contraception procedures of the study protocol.
- •Patients must be able to understand and be willing to comply with the requirements of the study protocol.
- •Patients participate voluntarily and sign informed consent form(s).
排除标准
- •Previous treatment with a MEK inhibitor or autophagy inhibitor.
- •Previous treatment with three or more lines of prior chemotherapy.
- •Extrahepatic CCA with recent (within 6 weeks) placement of a stent or episodes of unstable biliary stents (manifest as obstruction, migration of the stent, infevtion or mechanical failure of the stent) within 6 weeks according to investigator's judgement.
- •Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:
- •Cardiovascular disorders: congestive heart failure New York Heart Association ≥ class 2 or left ventricular ejection fraction (LVEF) <50%, arrythmias or cardiac conduction abnormalities. Uncontrolled arterial hypertension or inadequately controlled arterial hypertension, at the discretion of the investigator, based on an average of = >3 BP readings over = >2 sessions.
- •Patients who have retinal condition (retinal tear, exudate, hemorrhage) or history of retinal vein occlusion or central serous retinopathy or retinal pigment epithelial detachment.
- •History of interstitial lung disease or pneumonitis.
- •Patients who have clinically significant pleural effusion or ascites.
- •Patients who have neurological condition (e.g., tremor, ataxia, hypotension, confusion), history of seizures or active central nervous system metastases.
- •Impairment of gastrointestinal function or gastrointestinal disease (e.g., diarrhea, active ulcer disease, history of gastrointestinal perforation/hemorrhage, malabsorption or other conditions that under the judgment of the principal investigator (PI) may impair absorption of study drugs).
- •Patients who are taking antineoplastic drugs for concomitant cancer or history of malignancy other than CCA within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%) such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
- •Any other condition that would, in the Investigator s judgment, contraindicate the patients' participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection, unable to swallow medication, social/psychological issues, etc).
- •Known active viral hepatitis, including HBV and HCV.
- •Patients with known allergic reaction to quinoline derivatives (e.g., quinine, chloroquine, mefloquine) and/or hypersensitivity to study drugs.
- •Patients who have not recovered for certain AEs due to previous lines of therpay.
- •Female patients who are pregnant or lactating at the time of enrollment.
研究组 & 干预措施
GNS561+Trametinib
Experimental
Phase 1b Dose Finding Patients will receive GNS561 (50mg QD; 100mg QD; 150mg; 200mg QD) and trametinib (2mg QD; 1.5mg QD; 1mg QD) in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD) of the combination.
Experimental:
Phase 2a Patients will receive GNS561 and trametinib at the recommended dose of the combination determined during Phase 1b
干预措施: GNS561 + Trametinib (Drug)
结局指标
主要结局
Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b)
时间窗: At the end of Cycle 1 (each Cycle is 21 days)
Defined as Treatment Emergent Adverse Event (TEAE) being at least possibly related to study drug: With Grade ≥ 3 (using NCI CTCAE Version 5.0 or higher as applicable) such as specified in the protocol
Objective response rate (ORR) of the combination of GNS561 with trametinib (Phase 2a)
时间窗: Up to 11 months (estimated)
Defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
次要结局
- Time To Progression (TTP)(Up to 11 months (estimated))
- Disease Control Rate (DCR)(Up to 11 months (estimated))
- Duration of response (DoR)(Up to 11 months (estimated))
- Progression-free survival (PFS)(Up to 11 months (estimated))
- Time To Response (TTR)(Up to 11 months (estimated))
- Overall Survival (OS) time(Up to approximately 42 months)
- Drug concentration in plasma for GNS561 and trametinib(Predose to Day 21 of Cycle 1 and predose to Day 21 of Cycle 2 (each Cycle is 21 days))
- Incidence and severity of treatment emergent adverse event (TEAEs), incidence of serious adverse events (SAEs), incidence of TRAEs, incidence of adverse events of special interest (AESIs), rate of treatment discontinuation or interruption for TRAEs(Up to 11 months (estimated))
- Incidence of clinically significant changes or abnormalities from physical examinations, ophthalmologic assessments, vital signs, performance scores, laboratory results, ECGs, echocardiograms or multigated acquisition scans(Up to 11 months (estimated))
研究者
研究点 (20)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological MalignanciesRelapsed/Refractory Chronic Lymphocytic LeukemiaNCT05944978Sichuan Baili Pharmaceutical Co., Ltd.3
已完成
1 期
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)NCT05364424Hoffmann-La Roche43
已完成
1 期
A Phase I Study of TRN501 in Healthy VolunteersParkinson DiseaseNCT06453551SNLD, Ltd.72
已完成
1 期
A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue SarcomaSoft Tissue SarcomaNCT05301764Lyvgen Biopharma Holdings Limited39
进行中（未招募）
1 期
A study to assess the safety and tolerability of combining G1T28 with etoposide and carboplatin therapy and to evaluate the effect of G1T28 on blood cell production affected by chemotherapy.Extensive-Stage Small Cell Lung Cancer (SCLC)MedDRA version: 20.0Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001583-11-PLG1 Therapeutics96